SEC Comment Letter for Anixa Biosciences Inc (ANIX) (CIK 0000715446) (ANIX) — Jun 18, 2019
Anixa Biosciences Inc (ANIX) (CIK 0000715446)
Date: June 18, 2019 · CIK: 0000715446 · Accession: 0000000000-19-009951
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-232067
Letter
June 17, 2019 Amit Kumar President and Chief Executive Officer Anixa Biosciences, Inc 3150 Almaden Expressway, Suite 250 San Jose, CA 95118 Re:Anixa Biosciences, Inc Registration Statement on Form S-3 Filed June 11, 2019 File No. 333-232067 Dear Dr. Kumar: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ronald (Ron) Alper at 202-551-3329 with any questions. Sincerely, Division of Corporation Finance Office of Beverages, Apparel and Mining cc: Barry Grossman
Show Raw Text
June 17, 2019
Amit Kumar
President and Chief Executive Officer
Anixa Biosciences, Inc
3150 Almaden Expressway, Suite 250
San Jose, CA 95118
Re:Anixa Biosciences, Inc
Registration Statement on Form S-3
Filed June 11, 2019
File No. 333-232067
Dear Dr. Kumar:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ronald (Ron) Alper at 202-551-3329 with any questions.
Sincerely,
Division of Corporation Finance
Office of Beverages, Apparel and
Mining
cc: Barry Grossman